Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coherent (COHR) : Anyone else holding? -- Ignore unavailable to you. Want to Upgrade?

To: craig crawford who wrote (424)	1/23/1998 2:06:00 AM
From: Khris Vogel	Read Replies (1) \| Respond to of 788

So that makes mgmt. incompetent? Just because analysts didn't get all the guidance they'd hoped for spoon-fed to them at a time of their convenience? C'mon!! It is painfully obvious that the co. is doing some heavy R&D, even to the extent going out and acquiring assets from co.'s like AMOCO, Adlas, and Micracor, working hard to bring some new products to market. Maybe the analysts should get off their duffs and do their job, digging a little deeper than what IR passes along (sorry, I'm venting - I just read the article re: lazy analytical work on Oxford Health Plans in the Jan. SmartMoney). As to the increasing importance of R&D expenditures to COHR, from the lastest 10-Q: NEW PRODUCT INTRODUCTIONS. Coherent's future operating results are dependent on its ability to rapidly develop, manufacture and market technologically innovative products that meet customers' needs. In addition, after the products are developed, Coherent must quickly manufacture such products in sufficient volumes at acceptable costs to meet demand. Without the introduction of new products and product enhancements, Coherent's products are likely to become technologically obsolete, in which case inventory may be written off and revenues would be materially and adversely affected. There can be no assurance that such new products, if and when introduced, will receive market acceptance. However, Coherent anticipates that it will continue to incur significant research and development expenditures in order to maintain its competitive position with a continuing flow of innovative, high-quality products. As far as your impression of the CEO, I'm sorry to say that I missed the CNBC appearance you cite so as to see it for myself. What happened?

To: craig crawford who wrote (424)	1/23/1998 2:31:00 AM
From: Khris Vogel	Read Replies (1) \| Respond to of 788

In the Jan./Feb. issue of Bloomberg Personal, there is an article, "Wall Street Stars' Picks For '98," in which Robert Natale, editor of S&P's Emergency and Special Situations, picks COHR as having notable promise. The blurb says "Natale sees revenues of this leading maker of medical and scientfic lasers growing at 10%-15%, earnings up 15%-20%, during the next 3 to 5 years. Look for '98 earnings of $3.15 per share and P/E expansion." There is a target indicated of $59, but no time frame is provided.